Crain's Chicago Business

Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up.

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI has launched a $400 million funding round and ...

Inside PathosMind by Pathos Communications : Ten Leaders Driving Today's Most Newsworthy Conversations

Drawing on daily monitoring of more than 50,000 news publishers worldwide and analysis of conversations across a global ...
Crain's Chicago Business

Pathos raises $365 million in funding round, touts $1.6 billion valuation

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Pathos AI, the biotech drug developer spun out of Tempus ...

PathosMind by Pathos Communications Highlights Six Influential Leaders

By scanning more than 50,000 news publishers globally each day and analysing discussions across a worldwide network of ...
FierceBiotech

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
Yahoo Finance

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will ...